Sat, Dec 20, 2014, 9:38 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • eftrcsd eftrcsd Jun 23, 1998 11:28 AM Flag

    Geneva

    SkinKhound: the spikes have been pretty good
    trading for you and the chart has several 30-high 40's
    loops. It is one way to trade into a position. (I trade
    some and then have a long term batch, so I do not
    begrudge you your style and choice.)//IMO Amprenavir will
    become part of the standard of care of combo
    antiretroviral treatment, perhaps with another protease
    inhibitor with the way the research is going, e.g.
    suggestions of quadruple drug therapy, etc. As I have written
    elsewhere, one of the main concerns of combo tx. is to
    maximize efficacy while staying ahead of resistance
    patterns and cross resistance patterns (example: Crixivan
    cannot be used first because of X resistance, thereby
    reducing future therapeutic options, hence Sustiva IMHO).
    Ampreniavir pharmacokinetic profile is improved and the
    trials have used numerous combo options for the FDA pkg
    and a broad label is expected. This is good. // Here
    is something I think is significantly different:
    Amprenavir/VX_478 crosses the blood brain barrier, and this is will
    be very important to get at the virus where it hides
    in the body (brain, CSF) "viral reservoirs" and I
    believe it will be useful in the treatement of
    AIDS-related cognitive changes, i.e. dementia , a direct
    physiological result of HIV on the CNS. Nearly all patients
    with AIDS will develop HIV-related encephalopathy.
    Very grim. This goes beyond forgetfulness to agitation
    and psychosis. Amprenavir and the NNRT nevirapine
    might be key players here IMHO. The need: potentcy and
    selectivity.//Also, I think VRTX, with their structre-based design
    approach can delve into the mysteries of gp120 along with
    Progenics, Pharmacopeia and others. Cure vs. treatmetn, well
    we can only hope. Regards

 
VRTX
118.90+1.16(+0.99%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.